Quantum BioPharma Ltd.

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company focused on researching and developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders. Operating through its Biopharmaceutical Innovation and Strategic Investments segments, the company advances drug candidates at various development stages, including its lead compound Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis, currently advancing toward Phase 2 clinical trials. Additional pipeline assets include FSD-PEA for inflammatory diseases like mast cell activation syndrome, Lucid-PSYCH for major depressive disorder, and unbuzzd, a proprietary formulation of vitamins and minerals to support liver and brain function in relieving alcohol consumption effects. Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma drives core R&D efforts, while FSD Strategic Investments Inc. manages a portfolio of secured loans on residential and commercial properties. The company also holds an equity stake and royalties in Unbuzzd Wellness Inc. for the over-the-counter unbuzzd product, alongside a digital asset portfolio as part of its treasury strategy. Headquartered in Toronto, Quantum BioPharma plays a role in addressing unmet needs in central nervous system therapeutics and related health solutions.